doi:10.1080/19440049.2014.955538.[Taylor & Francis Online], [Web of Science ] , [Google Scholar])
History of acute pancreatitis Baseline characteristics Age - 55.85 yr Female sex - 57.1% Average body weight - 210 lbs (96 kg) Average BMI - 34.65 Type 2 diabetes - 55.9% Average ALT - 67.85 U/liter Average AST - 53.0 U/liter Fibrosis stage 2 - 31.3% Fibrosis stage 3 - 68.8% Randomized treatment groups Group 1 (534 patients): Semaglutide with a target dose of 2.4 mg once weekly Group 2 (266 patients): Placebo The starting dose of semaglutide was 0.25 mg once weekly, which was increased every 4 weeks to once-weekly doses of 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg until the target dose of 2.4 mg was reached after the 16-week dose-escalation period
So while this comparison raised questions about how the treatment stacks up against competitors, it doesnt necessarily affect its chances of approval
These medications mimic the hormone GLP-1 (glucagon-like peptide-1), which is naturally released after eating
84 The overexpression of circHECTD1 leads to increased expression levels of p62, ATG5, and ATG9 via the inhibition of miR-182-5p, which activates AMPK/mTOR signaling and reduces colonic injury and inflammation by promoting autophagy
